ARCHIVES

DCT Board Okays Contract Recompetitions, But Litton Bionetics May Be Barred From Two Supporting Gall’s Lab, Plus FCRF Program

This article is from The Cancer Letter archive.

Vol. 11 No. 41 | October 25, 1985

Download PDF Visit The Full Archive

Related Articles

Obama Plan Would Double Cancer Funding, Increase Clinical Trial Enrollment To 10%.

November 7, 2008

Gene Delivery System Targets Tumor Blood Vessels In Dogs

March 27, 2009

John Durant Names ASCO Executive NP; A New Position, New Voice In Washington

December 2, 1994

Communication Is Key To Clinical Trial Enrollment

June 30, 2006

Also Von Eschenbach’s NCI Farewell Reception, Gift Solicitation, Raises Legal And Ethical Issues.

May 5, 2006

Four RFAs Released For RM Program

November 6, 1981